Laura Aguilar, MD, PhD
- Co-Founder, Candel Therapeutics
Past Forum: 2022
Boston
Summary
The eight annual World Medical Innovation Forum was back in person in Boston.
This year, we gathered to discuss the extraordinary opportunities in gene and cell therapy and the profound impact they will have on medicine. In more than thirty sessions over the course of three days, Mass General Brigham’s Harvard faculty, industry experts and leading investors and entrepreneurs explored the technologies and challenges of gene and cell therapy as we continue to bring life-changing breakthroughs to our patients and millions around the world.
The World Medical Innovation Forum was established to reaffirm the importance of collaborative innovation—academia, industry and government working together to create solutions for medicine’s great challenges. Our goal is to provide actionable insights for Forum participants. We are grateful to the nearly 200 senior executives, investors, Harvard clinicians and investigators who shared their perspectives as speakers.
2022 Resources
Disruptive Dozen
Speakers
Tazeen Ahmad
- Managing Director, Global Research, BofA Securities
Galit Alter, PhD
- Principal Investigator, Ragon Institute, MGH
- Professor of Medicine, HMS
Irina Antonijevic, MD, PhD
- CMO and Head of R&D, Triplet Therapeutics, Inc.
Natalie Artzi, PhD
- Assistant Professor of Medicine, HMS
Christopher Baum, MD
- Chairman of the Board of Directors, Berlin Institute of Health at Charité (BIH)
James Beck, PhD
- CSO, Parkinson’s Foundation
Fengfeng Bei, PhD
- Principal Investigator, Department of Neurosurgery, BWH
- Assistant Professor of Neurosurgery, HMS
Paul Biddinger, MD
- Chief Preparedness and Continuity Officer, Mass General Brigham
- Associate Professor of Emergency Medicine, HMS
John Bishai, PhD
- Managing Director, Global Investment Banking, BofA Securities
Joseph Bonventre, MD, PhD
- Chief, Division of Renal Medicine, BWH
- Samuel A. Levine Distinguished Professor of Medicine and Constantine L. Hampers Distinguished Chair, HMS
Albert Bourla, PhD
- CEO, Pfizer Inc.
Sarah Boyce
- President & CEO, Avidity Biosciences, Inc.
Robert Bradway
- CEO, Amgen
Helen Branswell
- Senior Writer, STAT
David Brown, MD
- President, Massachusetts General Hospital
- Executive Vice President, Mass General Brigham
Lynn Bry, MD, PhD
- Director, Massachusetts Host-Microbiome Center, BWH
- Associate Professor of Pathology, HMS
Jim Burns, PhD
- CEO, Locanabio
Greg Butz
- Managing Director, Head of Life Sciences Investment Banking, BofA Securities
Pablo Cagnoni, MD
- CEO, Rubius Therapeutics
Robert Califf, MD
- Commissioner of Food and Drugs, US Food and Drug Administration
Bob Carter, MD, PhD
- Chairman, Department of Neurosurgery, MGH
- William and Elizabeth Sweet Professor of Neurosurgery, HMS
Marc Casper
- CEO, ThermoFisher
Miceal Chamberlain
- President of Massachusetts, Northeast Region Executive, Bank of America
Anil Chandraker, MD
- Medical Director of Kidney and Pancreas Transplantation, BWH
- Associate Professor of Medicine, HMS
Zheng-Yi Chen, DPhil
- Associate Scientist, Eaton-Peabody Laboratories, Mass Eye and Ear
- Associate Professor of Otolaryngology Head and Neck Surgery, HMS
Nino Chiocca, MD, PhD
- Neurosurgeon-in-Chief and Chairman, Neurosurgery, BWH
- Harvey W. Cushing Professor of Neurosurgery, HMS
Choi-Fong Cho, PhD
- Assistant Professor of Neurosurgery, BWH, HMS
Shelley Chu, MD, PhD
- Partner, Lightspeed
Chris Coburn
- Chief Innovation Officer, Mass General Brigham
Monica Coenraads
- CEO, Rett Syndrome Research Trust
Bertha Coombs
- Reporter, CNBC
David Corey, PhD
- Bertarelli Professor of Translational Medical Science, Neurobiology, HMS
Susan Cotman, PhD
- Assistant in Neuroscience, Center for Genomic Medicine, MGH
- Assistant Professor of Neurology, HMS
Christina Coughlin, MD, PhD
- CEO, CytoImmune
Merit Cudkowicz, MD
- Chair, Dept of Neurology, MGH
- Julieanne Dorn Professor of Neurology, HMS
Derik de Bruin, PhD
- Managing Director, Global Research, BofA Securities
Albert Edge, PhD
- Eaton Peabody Professor of Otolaryngology, HMS, Mass Eye and Ear
Florian Eichler, MD
- Director, Center for Rare Neurological Diseases, MGH
- Associate Professor of Neurology, HMS
Seth Ettenberg, PhD
- President & CEO, BlueRock Therapeutics
Rick Fair
- President & CEO, Bellicum
Anne Finucane
- Chairman of the Board, Bank of America Europe
John Fish
- Chairman & CEO, Suffolk
- Chair, Brigham and Women’s Hospital
Meredith Fisher, PhD
- Partner, Mass General Brigham Ventures
Alexandria Forbes, PhD
- President & CEO, MeiraGTx
Jean-François Formela, MD
- Partner, Atlas Venture
Christine Fox
- President, Novartis Gene Therapies
Matthew Frigault, MD
- Clinical Director, Cellular Immunotherapy Program, MGH
- Assistant Professor of Medicine, HMS
Nicholas Galakatos, PhD
- Global Head of Life Sciences, Blackstone
Annie Ganot
- VP, Head of Patient Advocacy, Solid Biosciences
Jason Gerberry
- Managing Director, Global Research, BofA Securities
Michael Gilmore, PhD
- Chief Scientific Officer, Mass Eye and Ear
- Sir William Osler Professor of Ophthalmology, HMS
Allan Goldstein, MD
- Chief of Pediatric Surgery, MGH
- Surgeon-in-Chief, MassGeneral for Children
- Marshall K. Bartlett Professor of Surgery, HMS
Robert Green, MD
- Director, Genomes2People Research Program, BWH
- Professor of Medicine, HMS
Yulia Grishchuk, PhD
- Assistant Investigator, Center for Genomic Medicine, MGH
- Assistant Professor of Neurology, HMS
Stephen Haggarty, PhD
- Director, Chemical Neurobiology Laboratory, Center for Genomic Medicine, MGH
- Associate Professor of Neurology, HMS
David Hallal
- Chairman & CEO, ElevateBio
Alexandria Hammond, PhD
- Associate, Global Research, BofA Securities
Erin Harris
- Chief Editor, Cell & Gene
Greg Harrison
- Vice President, Global Research, BofA Securities
Rachel Haurwitz, PhD
- President & CEO, Caribou Biosciences
Kristen Hege, MD
- Senior Vice President, Early Clinical Development, Hematology/Oncology & Cell Therapy, Bristol Myers Squibb
Todd Herrington, MD, PhD
- Director, Deep Brain Stimulation Program, MGH
- Assistant Professor of Neurology, HMS
Robert Higgins, MD, MSHA
- President, Brigham and Women’s Hospital
- Executive Vice President, Mass General Brigham
Colin Hill
- CEO, GNS Healthcare
Susan Hockfield, PhD
- President Emerita, MIT
Ole Isacson, MD, PhD
- Director, Neuroregeneration Research Institute, McLean
- Professor of Neurology & Neuroscience, HMS
Max Jan, PhD
- Principal Investigator, Center for Cancer Research, MGH
- Assistant Professor of Pathology, HMS
J. Keith Joung, MD, PhD
- Robert B. Colvin, M.D. Endowed Chair in Pathology & Pathologist, MGH
- Professor of Pathology, HMS
Carl June, MD
- Richard W. Vague Professor in Immunotherapy, Director, Center for Cellular Immunotherapies, Director, Parker Institute for Cancer Immunotherapy, University of Pennsylvania Perelman School of Medicine
Staci Kallish, DO
- President, Board of Directors, National Tay Sachs and Allied Diseases
- Medical Geneticist, Associate Professor of Clinical Medicine, Penn Medicine
Rosana Kapeller, MD, PhD
- Co-Founder, President & CEO, ROME Therapeutics
Sekar Kathiresan, MD
- CEO, Verve Therapeutics
Jason Kelly, PhD
- Co-Founder & CEO, Ginkgo Bioworks
Kwang-Soo Kim, PhD
- Director, Molecular Neurobiology Laboratory, McLean
- Professor of Neuroscience and Psychiatry, HMS
Roger Kitterman
- VP, Mass General Brigham Ventures
Anne Klibanski, MD
- President & CEO, Mass General Brigham
- Laurie Carrol Guthart Professor of Medicine, HMS
Stephen Knight, MD
- President & Managing Partner, F-Prime Capital
Adam Koppel, MD, PhD
- Managing Director, Bain Capital Life Sciences
Jonathan Kraft
- President, The Kraft Group
- Chairman of the Board of Trustees, MGH
Anna Krichevsky, PhD
- Associate Professor of Neurology, BWH, HMS
Daniel Krizek
- Portfolio Manager, Citadel
Daniel Kuritzkes, MD
- Chief, Division of Infectious Diseases, BWH
- Harriet Ryan Albee Professor of Medicine, HMS
Jeannie Lee, MD, PhD
- Molecular Biologist, MGH
- Professor of Genetics, HMS
Nick Leschly
- CEO, 2seventy bio
Josh Mandel-Brehm
- President & CEO, CAMP4 Therapeutics
Joel Marcus
- Executive Chairman & Founder, Alexandria Real Estate Equities, Inc.
James Markmann, MD, PhD
- Chief, Division of Transplant Surgery, MGH
- Claude E. Welch Professor of Surgery, HMS
Peter Marks, MD, PhD
- Director, Center for Biologics Evaluation and Research, FDA
Marcela Maus, MD, PhD
- Director, Cellular Immunotherapy Program, Cancer Center, MGH
- Associate Professor, Medicine, HMS
Terry McGuire
- Founding Partner, Polaris Partners
Rachel McMinn, PhD
- Founder & CEO, Neurogene
Geoff Meacham
- Managing Director, Global Research, BofA Securities
Maria Millan, MD
- President & CEO, California Institute for Regenerative Medicine
Marco Mineo, MD
- Instructor in Neurosurgery, BWH, HMS
Rick Modi
- CEO, Affinia Therapeutics
Brian Moynihan
- Chair & CEO, Bank of America
Sumit Mukherjee
- Managing Director & Head of Healthcare in Equity Capital Markets, BofA Securities
Richard Mulligan, PhD
- Mallinckrodt Professor of Genetics, Emeritus, HMS
- Executive Vice Chairman, Sana Biotechnology, Inc
Christopher Murphy
- Vice President Viral Vector Services, Thermo Fisher
Luigi Naldini, MD, PhD
- Director, San Raffaele Telethon Institute for Gene Therapy
Amir Nashat, PhD
- Managing Partner, Polaris Ventures
Sarah Nikiforow, MD, PhD
- Medical Director, Cell Manipulation Core Facility, Technical Director, Immune Effector Cell Therapy Program, DFCI
- Assistant Professor, HMS
Rebecca Oberman, PhD
- Executive Director, Mucolipidosis Type IV (ML4) Foundation
Michael Paglia
- COO, ElevateBio BaseCamp, ElevateBio
Spyros Papapetropoulos, MD, PhD
- CMO, Vigil Neuroscience
Pierpaolo Peruzzi, MD, PhD
- Neurosurgeon and Principal Investigator, BWH
- Assistant Professor of Neurosurgery, HMS
Andrew Plump, MD, PhD
- President, R&D, Takeda
Mark Poznansky, MD, PhD
- Director, Vaccine and Immunotherapy Center, MGH
- Professor of Medicine, HMS
Francisco Quintana, PhD
- Professor, Neurology, Ann Romney Center for Neurologic Diseases, BWH
- Kuchroo Weiner Distinguished Professor of Neuroimmunology, BWH
Harith Rajagopalan, MD, PhD
- CEO & Co-Founder, Fractyl Health
Vijaya Ramesh, PhD
- Co-Director of Neuroscience, Associate Geneticist in Neurology, MGH
- Professor of Neurology, HMS
Richard Ransohoff, MD
- CMO, Abata Therapeutics
- Venture Partner, Third Rock Ventures
Arati Rao, MD
- Senior Vice President, Clinical Development, PACT Pharma
Kendra Rose, PhD
- VP, Head of New Platforms, Ophthalmology and Hemophilia, Bayer
John Rossi
- VP Head of Translational Medicine, Syncopation Life Sciences
Issi Rozen
- Venture Partner, GV
Michael Ryskin
- Director, Global Research, BofA Securities
Bastiano Sanna, PhD
- EVP, Chief of Cell & Gene Therapies and VCGT Site Head, Vertex Pharmaceuticals
Vicki Sato, PhD
- Chairman of the Board, Vir Biotechnology
- Chairman, Denali Therapeutics
David Scadden, MD
- Director, Center for Regenerative Medicine, MGH
- Gerald and Darlene Jordan Professor of Medicine, HMS
Jeffrey Schweitzer, MD, PhD
- Neurosurgeon, MGH
- Assistant Professor of Neurosurgery, HMS
Christine Seidman, MD
- Director, Cardiovascular Genetics Center, BWH
- Smith Professor of Medicine & Genetics, HMS
Laura Sepp-Lorenzino, PhD
- Chief Scientific Officer, Executive Vice President, Intellia Therapeutics
Dhvanit Shah, PhD
- President & CEO, Garuda Therapeutics
Khalid Shah, PhD
- Vice Chairman of Research, Department of Neurosurgery, BWH
- Professor, HMS
Phillip Sharp, PhD
- Institute Professor and Professor of Biology, Koch Institute for Integrative Cancer Research at MIT
- Co-Founder, Alnylam Pharmaceuticals, Inc.
Norman Sharpless, MD
- Former Director, National Cancer Institute
Christi Shaw
- CEO, Kite, a Gilead Company
Adam Shaywitz, MD, PhD
- CMO, BridgeBio Gene Therapy
Angela Shen, MD
- Vice President, Strategic Innovation Leaders, Mass General Brigham Innovation
Erica Shenoy, MD, PhD
- Associate Chief, Infection Control Unit, MGH
- Associate Professor of Medicine, HMS
Rahul Singhvi, ScD
- CEO, National Resilience, Inc.
Daniel Skovronsky, MD, PhD
- Senior Vice President, Chief Scientific and Medical Officer, Eli Lilly and Company
Susan Slaugenhaupt, PhD
- Scientific Director and Elizabeth G. Riley and Daniel E. Smith Jr. Endowed Chair, Mass General Research Institute
- Professor, Neurology, HMS
Scott Sperling
- Co-Chief Executive Officer, Thomas H. Lee Partners
- Chairman of the Board of Directors, Mass General Brigham
Catherine Stehman-Breen, MD
- CEO, Chroma Medicine
Beth Stevens, PhD
- HHMI Investigator, F.M. Kirby Neurobiology Research Program, Boston Children’s Hospital
- Associate Professor of Neurology, HMS
Alec Stranahan, PhD
- Vice President, Equity Research, BofA Securities
Bakhos Tannous, PhD
- Director, Experimental Therapeutics Unit, Director, Viral Vector Core, MGH
- Professor of Neurology, HMS
Rudolph Tanzi, PhD
- Vice-Chair, Neurology, Director, Genetics and Aging Research Unit, MGH
- Joseph P. and Rose F. Kennedy Professor of Neurology, HMS
Ravi Thadhani, MD
- Chief Academic Officer, Mass General Brigham
Luk Vandenberghe, PhD
- Grousbeck Associate Professor in Gene Therapy, Mass General Brigham (on leave)
Demetrios Vavvas, MD, PhD
- Associate Director of the Retina Service, Mass Eye and Ear
- Solman and Libe Friedman Professor of Ophthalmology, Co-Director Ocular Regenerative Medical Institute, HMS
Rusty Williams, MD, PhD
- Chairman & CEO, Walking Fish Therapeutics
Janet Wu
- Anchor/Reporter, Bloomberg
Michael Young, PhD
- Director, Minda de Gunzburg Center for Retinal Regeneration, Associate Scientist, Schepens Eye Research Institute, Mass Eye and Ear
- Associate Professor of Ophthalmology, Co-Director, Ocular Regenerative Medicine Institute, HMS
Richard Young, PhD
- Professor, Whitehead Institute, MIT
Nerea Zabaleta, PhD
- Principal Investigator, Grousbeck Gene Therapy Center, Mass Eye and Ear
- Instructor in Ophthalmology, HMS
Jason Zemansky, PhD
- Vice President, Global Research, BofA Securities
Ran Zheng
- CEO, Landmark Bio
Panels
Monday, May 2, 2022
First Look: 8 rapid fire presentations on Mass General Brigham’s new GCT technologies
- Moderator: Meredith Fisher, PhD, Partner, Mass General Brigham Ventures
- Moderator: Roger Kitterman, VP, Mass General Brigham Ventures
Presenters:
- Bakhos Tannous, PhD, Director, Experimental Therapeutics Unit, Director, Viral Vector Core, MGH; Professor of Neurology, HMS
- Vijaya Ramesh, PhD, Co-Director of Neuroscience, Associate Geneticist in Neurology, MGH; Professor of Neurology, HMS
- Anna Krichevsky, PhD, Associate Professor of Neurology, BWH, HMS
- Nerea Zabaleta, PhD, Principal Investigator, Grousbeck Gene Therapy Center, Mass Eye and Ear; Instructor in Ophthalmology, HMS
- Francisco Quintana, PhD, Professor, Neurology, Ann Romney Center for Neurologic Diseases, BWH; Kuchroo Weiner Distinguished Professor of Neuroimmunology, BWH
- Stephen Haggarty, PhD, Director, Chemical Neurobiology Laboratory, Center for Genomic Medicine, MGH; Associate Professor of Neurology, HMS
- Michael Young, PhD, Director, Minda de Gunzburg Center for Retinal Regeneration, Associate Scientist, Schepens Eye Research Institute, Mass Eye and Ear; Associate Professor of Ophthalmology, Co-Director, Ocular Regenerative Medicine Institute, HMS
- Max Jan, MD, PhD, Principal Investigator, Center for Cancer Research, MGH; Assistant Professor of Pathology, HMS
First Look: 8 rapid fire presentations on Mass General Brigham’s new GCT technologies
- Moderator: Meredith Fisher, PhD, Partner, Mass General Brigham Ventures
- Moderator: Roger Kitterman, VP, Mass General Brigham Ventures
Presenters:
- Choi-Fong Cho, PhD, Assistant Professor of Neurosurgery, BWH, HMS
- Yulia Grishchuk, PhD, Assistant Investigator, Center for Genomic Medicine, MGH; Assistant Professor of Neurology, HMS
- Lynn Bry, MD, PhD, Director, Massachusetts Host-Microbiome Center, BWH; Associate Professor of Pathology, HMS
- David Corey, PhD, Bertarelli Professor of Translational Medical Science, Neurobiology, HMS
- Anil Chandraker, MD, Medical Director of Kidney and Pancreas Transplantation, BWH; Associate Professor of Medicine, HMS
- Ole Isacson, MD, PhD, Director, Neuroregeneration Research Institute, McLean; Professor of Neurology & Neuroscience, HMS
- Marco Mineo, PhD, Instructor in Neurosurgery, BWH, HMS
- Susan Cotman, PhD, Assistant in Neuroscience, Center for Genomic Medicine, MGH; Assistant Professor of Neurology, HMS
THE DR. IS IN | Gene and Epigenetic Editing in the Development of Treatment for Deafness
- Moderator: Geoff Meacham, PhD, Managing Director, Global Research, BofA Securities
- Albert Edge, PhD, Eaton Peabody Professor of Otolaryngology, HMS, Mass Eye and Ear
THE DR. IS IN | Single Gene Correction in the Brain: Delivering Where it Matters Most
- Moderator: Tazeen Ahmad, Managing Director, Global Research, BofA Securities
- Florian Eichler, MD, Director, Center for Rare Neurological Diseases, MGH; Associate Professor of Neurology, HMS
THE DR. IS IN | Repair, Replace, Regrow: The Advancement of Regenerative Medicine
- Moderator: Jason Zemansky, PhD, Vice President, Global Research, BofA Securities
- Joseph Bonventre, MD, PhD, Chief, Division of Renal Medicine, BWH; Samuel A. Levine Distinguished Professor of Medicine and Constantine L. Hampers Distinguished Chair, HMS
- David Scadden, MD, Director, Center for Regenerative Medicine, MGH; Gerald and Darlene Jordan Professor of Medicine, HMS
THE DR. IS IN | Smart Materials: Non-viral Vectors for Gene Therapy
- Moderator: Alec Stranahan, PhD, Vice President, Equity Research, BofA Securities
- Natalie Artzi, PhD, Assistant Professor of Medicine, HMS
- Moderator: Jason Gerberry, Managing Director, Global Research, BofA Securities
- Robert Green, MD, Director, Genomes2People Research Program, BWH; Professor of Medicine, HMS
- Adam Shaywitz, MD, PhD, CMO, BridgeBio Gene Therapy
THE DR. IS IN | Leveraging Novel Mechanisms for Accelerated Vaccine and Immunotherapy Development
- Moderator: Alexandria Hammond, PhD, Associate, Global Research, BofA Securities
- Mark Poznansky, MD, PhD, Director, Vaccine and Immunotherapy Center, MGH; Professor of Medicine, HMS
- Introducer: Scott Sperling, Co-Chief Executive Officer, Thomas H. Lee Partners; Chairman of the Board of Directors, Mass General Brigham
- Anne Klibanski, MD, President & CEO, Mass General Brigham; Laurie Carrol Guthart Professor of Medicine, HMS
- Brian Moynihan, Chair & CEO, Bank of America
- Moderator: Susan Hockfield, PhD, President Emerita, MIT
- Miceal Chamberlain, President of Massachusetts, Northeast Region Executive, Bank of America
- Marcela Maus, MD, PhD, Director, Cellular Immunotherapy Program, Cancer Center, MGH; Associate Professor, Medicine, HMS
- Geoff Meacham, PhD, Managing Director, Global Research, BofA Securities
- Ravi Thadhani, MD, Chief Academic Officer, Mass General Brigham
GCT’s Historic Potential | Priorities and Trade Offs
- Moderator: Jean-François Formela, MD, Partner, Atlas Venture
- Pablo Cagnoni, MD, CEO, Rubius Therapeutics
- Kristen Hege, MD, Senior Vice President, Early Clinical Development, Hematology/Oncology & Cell Therapy, Bristol Myers Squibb
- Andrew Plump, MD, PhD, President, R&D, Takeda
Catherine Stehman-Breen, MD, CEO, Chroma Medicine
Manufacturing | Process Control
- Moderator: John Bishai, PhD, Managing Director, Global Investment Banking, BofA Securities
- Christopher Murphy, Vice President Viral Vector Services, Thermo Fisher
- Michael Paglia, COO, ElevateBio BaseCamp, ElevateBio
- Rahul Singhvi, ScD, CEO, National Resilience, Inc.
- Ran Zheng, CEO, Landmark Bio
- Moderator: Luk Vandenberghe, PhD, Grousbeck Associate Professor in Gene Therapy, Mass General Brigham
Peter Marks, MD, PhD, Director, Center for Biologics Evaluation and Research, FDA
Clinical GCT Trial Design | Regulatory | Strategy, Innovation and Future Direction | Risk vs Hype
- Moderator: Angela Shen, MD, Vice President, Strategic Innovation Leaders, Mass General Brigham Innovation
- Laura Aguilar, MD, PhD, Co-Founder, Candel Therapeutics
- Matthew Frigault, MD, Clinical Director, Cellular Immunotherapy Program, MGH; Assistant Professor of Medicine, HMS
- Arati Rao, MD, Senior Vice President, Clinical Development, PACT Pharma
- John Rossi, VP Head of Translational Medicine, Syncopation Life Sciences
FIRESIDE | mRNA Opportunities: Lessons Learned, Priorities, and the Future of GCT
- Moderator: Geoff Meacham, PhD, Managing Director, Global Research, BofA Securities
- Albert Bourla, PhD, CEO, Pfizer Inc.
Tuesday, May 3, 2022
FIRESIDE | Robert Califf, MD, Commissioner Food and Drugs, FDA
- Moderator: Tazeen Ahmad, Managing Director, Global Research, BofA Securities
- Moderator: J. Keith Joung, MD, PhD, Robert B. Colvin, M.D. Endowed Chair in Pathology & Pathologist, MGH; Professor of Pathology, HMS
- Robert Califf, MD, Commissioner of Food and Drugs, US Food and Drug Administration
Living with COVID | Lessons Learned and Looking Ahead
- Introducer: Jonathan Kraft, President, The Kraft Group; Chairman of the Board of Trustees, MGH
- Moderator: David Brown, MD, President, Massachusetts General Hospital; Executive Vice President, Mass General Brigham
- Paul Biddinger, MD, Chief Preparedness and Continuity Officer, Mass General Brigham; Associate Professor of Emergency Medicine, HMS
- Helen Branswell, Senior Writer, STAT
- Daniel Kuritzkes, MD, Chief, Division of Infectious Diseases, BWH; Harriet Ryan Albee Professor of Medicine, HMS
- Erica Shenoy, MD, PhD, Associate Chief, Infection Control Unit, MGH; Associate Professor of Medicine, HMS
The Global Biotech Epicenter | New England Now and in 2030
- Moderator: Anne Finucane, Chairman of the Board, Bank of America Europe
- Seth Ettenberg, PhD, President & CEO, BlueRock Therapeutics
- Joel Marcus, Executive Chairman & Founder, Alexandria Real Estate Equities, Inc.
- Terry McGuire, Founding Partner, Polaris Partners
- Vicki Sato, PhD, Chairman of the Board, Vir Biotechnology; Chairman, Denali Therapeutics
- Phillip Sharp, PhD, Institute Professor and Professor of Biology, Koch Institute for Integrative Cancer Research at MIT; Co-Founder, Alnylam Pharmaceuticals, Inc.
- Moderator: Merit Cudkowicz, MD, Chair, Dept of Neurology, MGH; Julieanne Dorn Professor of Neurology, HMS
- James Beck, PhD, CSO, Parkinson’s Foundation
- Monica Coenraads, CEO, Rett Syndrome Research Trust
- Annie Ganot, VP, Head of Patient Advocacy, Solid Biosciences
- Staci Kallish, DO, President, Board of Directors, National Tay Sachs and Allied Diseases; Medical Geneticist, Associate Professor of Clinical Medicine, Penn Medicine
- Rebecca Oberman, PhD, Executive Director, Mucolipidosis Type IV (ML4) Foundation
FIRESIDE | Meeting the Moment: The Next Wave of Innovation in Cancer and Cardiology
- Moderator: Geoff Meacham, PhD, Managing Director, Global Research, BofA Securities
- Robert Bradway, CEO, Amgen
- Presenter: Miceal Chamberlain, President of Massachusetts, Northeast Region Executive, Bank of America
- Presenter: Nino Chiocca, MD, PhD, Neurosurgeon-in-Chief and Chairman, Neurosurgery, BWH; Harvey W. Cushing Professor of Neurosurgery, HMS
THE DR. IS IN | Personalizing Cancer Care through RNA Therapies
- Moderator: Jason Gerberry, Managing Director, Global Research, BofA Securities
- Pierpaolo Peruzzi, MD, PhD, Neurosurgeon and Principal Investigator, BWH; Assistant Professor of Neurosurgery, HMS
THE DR. IS IN | Designing for Success: Clinical Trial Approaches for Rare and Ultra-Rare Diseases
- Moderator: Tazeen Ahmad, Managing Director, Global Research, BofA Securities
- Demetrios Vavvas, MD, PhD, Associate Director of the Retina Service, Mass Eye and Ear; Solman and Libe Friedman Professor of Ophthalmology, Co-Director Ocular Regenerative Medical Institute, HMS
THE DR. IS IN | A New Hope: Cell Therapy and Transplantation for Parkinson’s Disease
- Moderator: Greg Harrison, Vice President, Global Research, BofA Securities
- Bob Carter, MD, PhD, Chairman, Department of Neurosurgery, MGH; William and Elizabeth Sweet Professor of Neurosurgery, HMS
- Todd Herrington, MD, PhD, Director, Deep Brain Stimulation Program, MGH; Assistant Professor of Neurology, HMS
- Kwang-Soo Kim, PhD, Director, Molecular Neurobiology Laboratory, McLean; Professor of Neuroscience and Psychiatry, HMS
- Jeffrey Schweitzer, MD, PhD, Neurosurgeon, MGH; Assistant Professor of Neurosurgery, HMS
THE DR. IS IN | The Inner Workings of Gene Therapy Manufacturing
- Moderator: Michael Ryskin, Director, Global Research, BofA Securities
- Sarah Nikiforow, MD, PhD, Medical Director, Cell Manipulation Core Facility, Technical Director, Immune Effector Cell Therapy Program, DFCI; Assistant Professor, HMS
THE DR. IS IN | The Road Ahead: Regulatory Challenges for Gene and Cell Therapy
- Moderator: Geoff Meacham, PhD, Managing Director, Global Research, BofA Securities
- Peter Marks, MD, PhD, Director, Center for Biologics Evaluation and Research, FDA
THE DR. IS IN | The Mysterious Dark Genome
- Moderator: Angela Shen, MD, Vice President, Strategic Innovation Leaders, Mass General Brigham Innovation
- Moderator: Richard Young, PhD, Professor, Whitehead Institute, MIT
- Rosana Kapeller, MD, PhD, Co-Founder, President & CEO, ROME Therapeutics
- Josh Mandel-Brehm, President & CEO, CAMP4 Therapeutics
- Amir Nashat, PhD, Managing Partner, Polaris Ventures
- Issi Rozen, Venture Partner, GV
Capital Formation | Shaping Innovation
- Moderator: Greg Butz, Managing Director, Head of Life Sciences Investment Banking, BofA Securities
- Moderator: Sumit Mukherjee, Managing Director & Head of Healthcare in Equity Capital Markets, BofA Securities
- Shelley Chu, MD, PhD, Partner, Lightspeed
- Stephen Knight, MD, President & Managing Partner, F-Prime Capital
- Adam Koppel, MD, PhD, Managing Director, Bain Capital Life Sciences
- Daniel Krizek, Portfolio Manager, Citadel
FIRESIDE | Ending Cancer as We Know It: The Game Changing Potential of GCT
- Moderator: Erin Harris, Chief Editor, Cell & Gene
- David Scadden, MD, Director, Center for Regenerative Medicine, MGH; Gerald and Darlene Jordan Professor of Medicine, HMS
- Norman Sharpless, MD, Former Director, National Cancer Institute
FIRESIDE | Vision and Execution: Curing Disease with Cell Therapies
- Moderator: Marcela Maus, MD, PhD, Director, Cellular Immunotherapy Program, Cancer Center, MGH
Associate Professor, Medicine, HMS - Moderator: Ravi Thadhani, MD, Chief Academic Officer, Mass General Brigham
- Carl June, MD, Richard W. Vague Professor in Immunotherapy, Director, Center for Cellular Immunotherapies, Director, Parker Institute for Cancer Immunotherapy, University of Pennsylvania Perelman School of Medicine
GCT Development Centers | Academia’s Unique Contribution
- Moderator: Ravi Thadhani, MD, Chief Academic Officer, Mass General Brigham
- Carl June, MD, Richard W. Vague Professor in Immunotherapy, Director, Center for Cellular Immunotherapies, Director, Parker Institute for Cancer Immunotherapy, University of Pennsylvania Perelman School of Medicine
- Maria Millan, MD, President & CEO, California Institute for Regenerative Medicine
- Richard Mulligan, PhD, Mallinckrodt Professor of Genetics, Emeritus, HMS; Executive Vice Chairman, Sana Biotechnology, Inc
- Norman Sharpless, MD, Former Director, National Cancer Institute
- Moderator: Derik de Bruin, PhD, Managing Director, Global Research, BofA Securities
- Marc Casper, CEO, ThermoFisher
Gene and Cell Therapy | The World Speaks
- Moderator: Christine Fox, President, Novartis Gene Therapies
- Christopher Baum, MD, Chairman of the Board of Directors, Berlin Institute of Health at Charité (BIH)
- Nicholas Galakatos, PhD, Global Head of Life Sciences, Blackstone
- Luigi Naldini, MD, PhD, Director, San Raffaele Telethon Institute for Gene Therapy
- Kendra Rose, PhD, VP, Head of New Platforms, Ophthalmology and Hemophilia, Bayer
Control or Mitigation of the Effects of Chronic Neuroinflammation
- Moderator: Ole Isacson, MD, PhD, Director, Neuroregeneration Research Institute, McLean; Professor of Neurology & Neuroscience, HMS
- Colin Hill, CEO, GNS Healthcare
- Spyros Papapetropoulos, MD, PhD, CMO, Vigil Neuroscience
- Richard Ransohoff, MD, CMO, Abata Therapeutics; Venture Partner, Third Rock Ventures
- Beth Stevens, PhD, HHMI Investigator, F.M. Kirby Neurobiology Research Program, Boston Children’s Hospital; Associate Professor of Neurology, HMS
- Rudolph Tanzi, PhD, Vice-Chair, Neurology, Director, Genetics and Aging Research Unit, MGH; Joseph P. and Rose F. Kennedy Professor of Neurology, HMS
Wednesday, May 4, 2022
The Cell Therapy Landscape | CAR-T to Stem Cells
- Moderator: Marcela Maus, MD, PhD, Director, Cellular Immunotherapy Program, Cancer Center, MGH; Associate Professor, Medicine, HMS
- Christina Coughlin, MD, PhD, CEO, CytoImmune
- Rachel Haurwitz, PhD, President & CEO, Caribou Biosciences
- Nick Leschly, CEO, 2seventy bio
- Dhvanit Shah, PhD, President & CEO, Garuda Therapeutics
- Rusty Williams, MD, PhD, Chairman & CEO, Walking Fish Therapeutics
- Introducer: John Fish, Chairman & CEO, Suffolk; Chair, Brigham and Women’s Hospital
- Moderator: Robert Higgins, MD, President, Brigham and Women’s Hospital; Executive Vice President, Mass General Brigham
- Irina Antonijevic, MD, PhD, CMO and Head of R&D, Triplet Therapeutics, Inc.
- Rachel McMinn, PhD, Founder & CEO, Neurogene
- Harith Rajagopalan, MD, PhD, CEO & Co-Founder, Fractyl Health
- Bastiano Sanna, PhD, EVP, Chief of Cell & Gene Therapies and VCGT Site Head, Vertex Pharmaceuticals
- Jeffrey Schweitzer, MD, PhD, Neurosurgeon, MGH; Assistant Professor of Neurosurgery, HMS
- Moderator: Geoff Meacham, PhD, Managing Director, Global Research, BofA Securities
- Daniel Skovronsky, MD, PhD, Senior Vice President, Chief Scientific and Medical Officer, Eli Lilly and Company
FIRESIDE | Reimagining GCT Production
- Moderator: Derik de Bruin, PhD, Managing Director, Global Research, BofA Securities
- Jason Kelly, PhD, Co-Founder & CEO, Ginkgo Bioworks
Gene and Cell Therapy Safety | Enduring Framework Required
- Moderator: Christine Seidman, MD, Director, Cardiovascular Genetics Center, BWH; Smith Professor of Medicine & Genetics, HMS
- Rick Fair, President & CEO, Bellicum
- Alexandria Forbes, PhD, President & CEO, MeiraGTx
- Sekar Kathiresan, MD, CEO, Verve Therapeutics
Rick Modi, CEO, Affinia Therapeutics
RNA Therapeutics | Lessons Learned
- Moderator: Janet Wu, Anchor/Reporter, Bloomberg
- Sarah Boyce, President & CEO, Avidity Biosciences, Inc.
- Jim Burns, PhD, CEO, Locanabio
- Jeannie Lee, MD, PhD, Molecular Biologist, MGH; Professor of Genetics, HMS
- Laura Sepp-Lorenzino, PhD, Chief Scientific Officer, Executive Vice President, Intellia Therapeutics
Disruptive Dozen: 12 Technologies That Will Reinvent GCT in the Next Five Years
- Moderator: Nino Chiocca, MD, PhD, Neurosurgeon-in-Chief and Chairman, Neurosurgery, BWH; Harvey W. Cushing Professor of Neurosurgery, HMS
- Moderator: Susan Slaugenhaupt, PhD, Scientific Director and Elizabeth G. Riley and Daniel E. Smith Jr. Endowed Chair, Mass General Research Institute; Professor, Neurology, HMS
- Moderator: Ravi Thadhani, MD, Chief Academic Officer, Mass General Brigham
- Galit Alter, PhD, Principal Investigator, Ragon Institute, MGH; Professor of Medicine, HMS
- Natalie Artzi, PhD, Assistant Professor of Medicine, HMS
- Fengfeng Bei, PhD, Principal Investigator, Department of Neurosurgery, BWH; Assistant Professor of Neurosurgery, HMS
- Zheng-Yi Chen, DPhil, Associate Scientist, Eaton-Peabody Laboratories, Mass Eye and Ear; Associate Professor of Otolaryngology Head and Neck Surgery, HMS
- Matthew Frigault, MD, Clinical Director, Cellular Immunotherapy Program, MGH; Assistant Professor of Medicine, HMS
- Michael Gilmore, PhD, Chief Scientific Officer, Mass Eye and Ear; Sir William Osler Professor of Ophthalmology, HMS
- Allan Goldstein, MD, Chief of Pediatric Surgery, MGH; Surgeon-in-Chief, MassGeneral for Children
- Anna Krichevsky, PhD, Associate Professor of Neurology, BWH, HMS
- Jeannie Lee, MD, PhD, Molecular Biologist, MGH; Professor of Genetics, HMS
- James Markmann, MD, PhD, Chief, Division of Transplant Surgery, MGH; Claude E. Welch Professor of Surgery, HMS
- Khalid Shah, PhD, Vice Chairman of Research, Department of Neurosurgery, BWH; Professor, HMS
- Demetrios Vavvas, MD, PhD, Associate Director of the Retina Service, Mass Eye and Ear; Solman and Libe Friedman Professor of Ophthalmology, Co-Director Ocular Regenerative Medical Institute, HMS
Sponsors
